目的 探究金龙胶囊联合DP方案（顺铂＋多西他赛）治疗中晚期宫颈癌的有效性和安全性。方法 选择2012年3月—2015年3月在新野县人民医院就诊的中晚期宫颈癌患者56例，随机分成对照组和治疗组，每组各28例。对照组静脉滴注多西他赛注射液，60 mg/m²溶于生理盐水，1 h内滴注完毕，1次/3周；同时静脉滴注注射用顺铂（冻干型），50 mg/m²溶于生理盐水，1次/3周。治疗组在对照组基础上口服金龙胶囊，4粒/次，3次/d。两组患者均连续治疗6周。观察两组患者临床疗效，同时比较治疗前后两组患者中远期临床疗效、KPS评分和肿瘤直径及不良反应情况。结果 治疗后，对照组客观缓解率和疾病控制率分别为42.86%、64.29%，均分别显著低于治疗组的75.00%、89.29%，两组比较差异具有统计学意义（P<0.05）。治疗后，治疗组患者的局部复发率、远处转移率均显著低于对照组患者，3年生存率显著高于对照组患者，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者的KPS评分明显升高（P<0.05），肿瘤直径显著缩小（P<0.05），且治疗后治疗组患者KPS评分和肿瘤直径明显优于对照组（P<0.05）。治疗期间，治疗组患者药物不良反应发生率为10.71%，显著低于对照组患者的39.29%，两组比较差异具有统计学意义（P<0.05）。结论 金龙胶囊联合DP方案治疗中晚期宫颈癌疗效显著，不良反应发生率低，具有一定的临床推广应用价值。

Objective To explore the efficacy and safety of Jinlong Capsules combined with DP regimen in treatment of intermediate-advanced cervical cancer. Methods Patients (56 cases) with intermediate-advanced cervical cancer in Xinye County People's Hospital from March 2012 to March 2015 were randomly divided into control and treatment groups, and each had 28 cases. Patients in the control group were iv administered with Docetaxel Injection, 60 mg/m² added into normal saline, and dripped within 1 h, once every 3 weeks, and at the same time, they were iv administered with Cisplatin for injection, 50 mg/m² added into normal saline, once every 3 weeks. Patients in the treatment group were po administered with Jinlong Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacy was evaluated, and the long-term clinical efficacy, KPS score and tumor diameter, adverse reactions in two groups before and after treatment were compared. Results After treatment, the objective reaction rate and clinical benefit rate in the control group were 42.86% and 64.29%, which were significantly lower than 75.00% and 89.29% in the treatment group, respectively, and there were differences between two groups (P<0.05). After treatment, the local recurrence rate and distant metastasis rate in the treatment group were significantly lower than those in the control group, and 3 year survival rate was significantly higher than that in the control group, with significant difference between two groups (P<0.05). After treatment, the KPS scores in two groups were significantly increased (P<0.05), but tumor diameter was significantly decreased (P<0.05), and the KPS scores and tumor diameter in the treatment group were significantly lower than those in the control group (P<0.05). During the treatment, the adverse reactions rate in the treatment group was 10.71%, which was significantly lower than 39.29% in the control group, with significant difference between two groups (P<0.05). Conclusion Jinlong Capsules combined with DP regimen has significant curative effect in treatment of intermediate-advanced cervical cancer with lower incidence of adverse reactions, which has a certain clinical application value.